世界の経口血糖降下薬市場予測（～2028年）：スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤

• 英文タイトル：Global Oral Hypoglycemic Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8913 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

経口血糖降下薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界の経口血糖降下薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 経口血糖降下薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤 用途別セグメントは次のように区分されます。 ・病院、クリニック、その他 世界の経口血糖降下薬市場の主要な市場プレーヤーは以下のとおりです。 ・Pfizer、AstraZeneca、Johnson & Johnson、GlaxoSmithKline、Merck & Co、Eli Lilly、Sanofi、Takeda Pharmaceuticals、Novo Nordisk、Servier Laboratories、Boehringer Ingelheim、Bristol-Myers Squibb 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、経口血糖降下薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な経口血糖降下薬メーカーの企業概要、2019年～2022年までの経口血糖降下薬の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な経口血糖降下薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別経口血糖降下薬の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの経口血糖降下薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での経口血糖降下薬市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および経口血糖降下薬の産業チェーンを掲載しています。 ・第13、14、15章では、経口血糖降下薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、AstraZeneca、Johnson & Johnson、GlaxoSmithKline、Merck & Co、Eli Lilly、Sanofi、Takeda Pharmaceuticals、Novo Nordisk、Servier Laboratories、Boehringer Ingelheim、Bristol-Myers Squibb ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：スルホニル尿素剤（SU）、ダブルグアニジン、グルコシダーゼ阻害剤、インスリン相乗剤 ・用途別分析2017年-2028年：病院、クリニック、その他 ・経口血糖降下薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・経口血糖降下薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・経口血糖降下薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・経口血糖降下薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・経口血糖降下薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Oral Hypoglycemic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Oral Hypoglycemic Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Oral Hypoglycemic Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Sulfonylureas (SU) segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Oral Hypoglycemic Drugs include Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, and Merck & Co, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Oral Hypoglycemic Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Sulfonylureas (SU)
Double Guanidine
Glucosidase Inhibitor
Insulin Synergist
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Oral Hypoglycemic Drugs market are listed below:
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Hypoglycemic Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oral Hypoglycemic Drugs, with price, sales, revenue and global market share of Oral Hypoglycemic Drugs from 2019 to 2022.
Chapter 3, the Oral Hypoglycemic Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Hypoglycemic Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Oral Hypoglycemic Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Oral Hypoglycemic Drugs.
Chapter 13, 14, and 15, to describe Oral Hypoglycemic Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Oral Hypoglycemic Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oral Hypoglycemic Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Sulfonylureas (SU)
1.2.3 Double Guanidine
1.2.4 Glucosidase Inhibitor
1.2.5 Insulin Synergist
1.3 Market Analysis by Application
1.3.1 Overview: Global Oral Hypoglycemic Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Oral Hypoglycemic Drugs Market Size & Forecast
1.4.1 Global Oral Hypoglycemic Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Oral Hypoglycemic Drugs Sales in Volume (2017-2028)
1.4.3 Global Oral Hypoglycemic Drugs Price (2017-2028)
1.5 Global Oral Hypoglycemic Drugs Production Capacity Analysis
1.5.1 Global Oral Hypoglycemic Drugs Total Production Capacity (2017-2028)
1.5.2 Global Oral Hypoglycemic Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Oral Hypoglycemic Drugs Market Drivers
1.6.2 Oral Hypoglycemic Drugs Market Restraints
1.6.3 Oral Hypoglycemic Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Oral Hypoglycemic Drugs Product and Services
2.1.4 Pfizer Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca Oral Hypoglycemic Drugs Product and Services
2.2.4 AstraZeneca Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Oral Hypoglycemic Drugs Product and Services
2.3.4 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Oral Hypoglycemic Drugs Product and Services
2.4.4 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Merck & Co
2.5.1 Merck & Co Details
2.5.2 Merck & Co Major Business
2.5.3 Merck & Co Oral Hypoglycemic Drugs Product and Services
2.5.4 Merck & Co Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Eli Lilly
2.6.1 Eli Lilly Details
2.6.2 Eli Lilly Major Business
2.6.3 Eli Lilly Oral Hypoglycemic Drugs Product and Services
2.6.4 Eli Lilly Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Oral Hypoglycemic Drugs Product and Services
2.7.4 Sanofi Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Takeda Pharmaceuticals
2.8.1 Takeda Pharmaceuticals Details
2.8.2 Takeda Pharmaceuticals Major Business
2.8.3 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product and Services
2.8.4 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Novo Nordisk
2.9.1 Novo Nordisk Details
2.9.2 Novo Nordisk Major Business
2.9.3 Novo Nordisk Oral Hypoglycemic Drugs Product and Services
2.9.4 Novo Nordisk Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Servier Laboratories
2.10.1 Servier Laboratories Details
2.10.2 Servier Laboratories Major Business
2.10.3 Servier Laboratories Oral Hypoglycemic Drugs Product and Services
2.10.4 Servier Laboratories Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Boehringer Ingelheim
2.11.1 Boehringer Ingelheim Details
2.11.2 Boehringer Ingelheim Major Business
2.11.3 Boehringer Ingelheim Oral Hypoglycemic Drugs Product and Services
2.11.4 Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Bristol-Myers Squibb
2.12.1 Bristol-Myers Squibb Details
2.12.2 Bristol-Myers Squibb Major Business
2.12.3 Bristol-Myers Squibb Oral Hypoglycemic Drugs Product and Services
2.12.4 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Oral Hypoglycemic Drugs Breakdown Data by Manufacturer
3.1 Global Oral Hypoglycemic Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Oral Hypoglycemic Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Oral Hypoglycemic Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Oral Hypoglycemic Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Oral Hypoglycemic Drugs Manufacturer Market Share in 2021
3.5 Global Oral Hypoglycemic Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Oral Hypoglycemic Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Oral Hypoglycemic Drugs Market Size by Region
4.1.1 Global Oral Hypoglycemic Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Oral Hypoglycemic Drugs Revenue by Region (2017-2028)
4.2 North America Oral Hypoglycemic Drugs Revenue (2017-2028)
4.3 Europe Oral Hypoglycemic Drugs Revenue (2017-2028)
4.4 Asia-Pacific Oral Hypoglycemic Drugs Revenue (2017-2028)
4.5 South America Oral Hypoglycemic Drugs Revenue (2017-2028)
4.6 Middle East and Africa Oral Hypoglycemic Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Oral Hypoglycemic Drugs Sales in Volume by Type (2017-2028)
5.2 Global Oral Hypoglycemic Drugs Revenue by Type (2017-2028)
5.3 Global Oral Hypoglycemic Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Oral Hypoglycemic Drugs Sales in Volume by Application (2017-2028)
6.2 Global Oral Hypoglycemic Drugs Revenue by Application (2017-2028)
6.3 Global Oral Hypoglycemic Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Oral Hypoglycemic Drugs Sales by Type (2017-2028)
7.2 North America Oral Hypoglycemic Drugs Sales by Application (2017-2028)
7.3 North America Oral Hypoglycemic Drugs Market Size by Country
7.3.1 North America Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Oral Hypoglycemic Drugs Sales by Type (2017-2028)
8.2 Europe Oral Hypoglycemic Drugs Sales by Application (2017-2028)
8.3 Europe Oral Hypoglycemic Drugs Market Size by Country
8.3.1 Europe Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Oral Hypoglycemic Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Oral Hypoglycemic Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Oral Hypoglycemic Drugs Market Size by Region
9.3.1 Asia-Pacific Oral Hypoglycemic Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Oral Hypoglycemic Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Oral Hypoglycemic Drugs Sales by Type (2017-2028)
10.2 South America Oral Hypoglycemic Drugs Sales by Application (2017-2028)
10.3 South America Oral Hypoglycemic Drugs Market Size by Country
10.3.1 South America Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Oral Hypoglycemic Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Oral Hypoglycemic Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Oral Hypoglycemic Drugs Market Size by Country
11.3.1 Middle East & Africa Oral Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Oral Hypoglycemic Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Oral Hypoglycemic Drugs
12.3 Oral Hypoglycemic Drugs Production Process
12.4 Oral Hypoglycemic Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Oral Hypoglycemic Drugs Typical Distributors
13.3 Oral Hypoglycemic Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---